Business Context and Reporting Period
This Form 8-K Current Report covers events occurring between January 2, 2010, and April 9, 2010, for Anavex Life Sciences Corp., a Nevada corporation headquartered in Athens, Greece. The filing details material agreements, unregistered equity sales, and significant changes in executive leadership.
Key Financial Metrics and Agreements
- Financing Activities:
- Secured a $1,000,000 unsecured convertible loan at 20% annual interest, due February 22, 2012, with a conversion price of $2.35 per share.
- Conducted a private placement selling 92,499 units (stock and warrants) at $2.60 per unit, generating gross proceeds of $240,497.50.
- Settled a $100,000 promissory note balance by issuing 49,505 shares of common stock.
- Operating Expenses and Obligations:
- Entered a three-year lease for research facilities at $125,000 per month.
- Executed a two-year consulting agreement with Executive Chairman Cameron Durrant at $25,000 per month ($300,000 annual base).
- Extended the consulting agreement for President Harvey Lalach at $12,500 per month through January 31, 2011.
- Equity Adjustments: Re-priced 600,000 stock options for directors to an exercise price of $3.10 per share.
Material Changes Versus Prior Period
- Executive Leadership: Terminated the consulting agreement with former CEO Dr. Herve de Kergrohen on March 1, 2010, citing an inability to secure necessary financing for Phase 1 clinical trials. President Harvey Lalach assumed the role of principal executive officer.
- Capital Structure: Issued unregistered securities to settle debt and raise capital, increasing the outstanding share count.
- Cost Structure: Increased fixed monthly obligations significantly through new facility leases and executive compensation packages.
Outlook, Risks, and Management Commentary
- Operational Focus: The company is actively securing research facilities to conduct its research and development program.
- Financing Risks: The departure of the former CEO was explicitly linked to the failure to secure significant financings required for Phase 1 clinical trials and working capital.
- Liquidity and Debt: The company has taken on high-interest debt (20% convertible loan) and increased monthly burn rate via leases and executive fees, indicating a need for continued capital access.
- Regulatory Status: Recent equity issuances were conducted under Regulation S exemptions for non-U.S. persons.
Investor Verification Checklist
- Verify the company's current cash position and runway given the new $125,000 monthly lease and increased executive compensation.
- Confirm the status of Phase 1 clinical trial funding following the departure of the CEO responsible for securing it.
- Review the dilution impact of the $1,000,000 convertible loan and recent private placement on existing shareholders.
- Assess the implications of the stock option re-pricing for directors on future equity incentives.
- Check for any subsequent filings regarding the repayment terms or conversion of the high-interest convertible loan.